Bankrupt Drugmaker Vivus Gets Approval to Preserve Tax Breaks 2020/07/08 19:42:00 The Wall Street Journal
Vivus, which filed for bankruptcy with plans to be acquired by Carl Icahn’s investment firm, received interim court approval to preserve $648 million in net operating losses that could be used to reduce future taxes.
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy 2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.